EDIT vs EXAS · rev $32.3M vs rev $2.76B
Editas Medicine Inc (EDIT) versus EXACT Sciences Corporation (EXAS) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
EDIT currently screens at market cap $375.2M. EXAS currently screens at market cap $20.03B.
Not investment advice. Open the EDIT and EXAS stock pages for the full models.
Not investment advice.